More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $221.23 |
|
|||
| Open | $221.37 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $222.35 | ||||
| Day Low | $215.37 | ||||
| P/E | 46.96 | ||||
| EPS | $4.61 | ||||
| Volume | 9,646,087 | ||||
- AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 3.2% Yield
- AbbVie Declares Quarterly Dividend
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- FDA approves ABBVIE neck wrinkle injectable SKINVIVE by JUVÉDERM
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- Leerink highlights drug demand rebound after Memorial Day
- AbbVie presents nine-year venetoclax trial results at EHA congress
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resu
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie to present blood cancer data at EHA 2026
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
